AIM/HYPOTHESIS: Individuals at risk of developing type 2 diabetes show a progressive decline in insulin secretion and increased insulin resistance over time. However, inability of the beta cells to compensate for the increased insulin resistance represents a key defect leading to overt type 2 diabetes. The aims of the present study were to replicate the association between genetic variants of the PCSK2 gene and insulin secretion, and to explore the effect on risk of type 2 diabetes. METHODS: Replication of PCSK2 variants against insulin secretion included 7,682 non-diabetic Scandinavian individuals. Insulin secretion was measured as the corrected insulin response or disposition index, i.e. insulin secretion adjusted for the degree of insulin resistance. Risk of type 2 diabetes was studied in 28,287 Scandinavian individuals. RESULTS: The C-allele of PCSK2 rs2208203 was associated with reduced insulin secretion measured as the corrected insulin response (n = 8,151; β = -0.112, p = 1.3 × 10(-6)) as well as disposition index (n = 8,078, β = -0.128, p = 1.6 × 10(-7)). The variant was also associated with lower fasting glucagon levels (β = -0.084, p = 0.005) in non-diabetic individuals with a fasting plasma glucose of over 5.5 mmol/l. In human pancreatic islets, PCSK2 expression correlated negatively with HbA(1c) (n = 133, r = -0.196, p = 0.038), and showed a tendency to be lower in hyperglycaemic (HbA(1c) ≥6.0% or type 2 diabetes; n = 47, p = 0.13) than normoglycaemic (HbA(1c) >6.0%; n = 66) donors. The presence of the PCSK2 rs2208203 risk allele did not influence gene expression, nor did it show an apparent risk in terms of type 2 diabetes. CONCLUSIONS/ INTERPRETATION: A variant of the PCSK2 gene was associated with reduced glucose-stimulated insulin secretion, but also with lower glucagon levels, which could potentially counteract the effects of decreased insulin secretion on the risk of type 2 diabetes.
AIM/HYPOTHESIS: Individuals at risk of developing type 2 diabetes show a progressive decline in insulin secretion and increased insulin resistance over time. However, inability of the beta cells to compensate for the increased insulin resistance represents a key defect leading to overt type 2 diabetes. The aims of the present study were to replicate the association between genetic variants of the PCSK2 gene and insulin secretion, and to explore the effect on risk of type 2 diabetes. METHODS: Replication of PCSK2 variants against insulin secretion included 7,682 non-diabetic Scandinavian individuals. Insulin secretion was measured as the corrected insulin response or disposition index, i.e. insulin secretion adjusted for the degree of insulin resistance. Risk of type 2 diabetes was studied in 28,287 Scandinavian individuals. RESULTS: The C-allele of PCSK2rs2208203 was associated with reduced insulin secretion measured as the corrected insulin response (n = 8,151; β = -0.112, p = 1.3 × 10(-6)) as well as disposition index (n = 8,078, β = -0.128, p = 1.6 × 10(-7)). The variant was also associated with lower fasting glucagon levels (β = -0.084, p = 0.005) in non-diabetic individuals with a fasting plasma glucose of over 5.5 mmol/l. In humanpancreatic islets, PCSK2 expression correlated negatively with HbA(1c) (n = 133, r = -0.196, p = 0.038), and showed a tendency to be lower in hyperglycaemic (HbA(1c) ≥6.0% or type 2 diabetes; n = 47, p = 0.13) than normoglycaemic (HbA(1c) >6.0%; n = 66) donors. The presence of the PCSK2rs2208203 risk allele did not influence gene expression, nor did it show an apparent risk in terms of type 2 diabetes. CONCLUSIONS/ INTERPRETATION: A variant of the PCSK2 gene was associated with reduced glucose-stimulated insulin secretion, but also with lower glucagon levels, which could potentially counteract the effects of decreased insulin secretion on the risk of type 2 diabetes.
Authors: R L Hanson; R E Pratley; C Bogardus; K M Narayan; J M Roumain; G Imperatore; A Fagot-Campagna; D J Pettitt; P H Bennett; W C Knowler Journal: Am J Epidemiol Date: 2000-01-15 Impact factor: 4.897
Authors: Valeriya Lyssenko; Peter Almgren; Dragi Anevski; Roland Perfekt; Kaj Lahti; Michael Nissén; Bo Isomaa; Björn Forsen; Nils Homström; Carola Saloranta; Marja-Riitta Taskinen; Leif Groop; Tiinamaija Tuomi Journal: Diabetes Date: 2005-01 Impact factor: 9.461
Authors: G Berglund; P Nilsson; K F Eriksson; J A Nilsson; B Hedblad; H Kristenson; F Lindgärde Journal: J Intern Med Date: 2000-01 Impact factor: 8.989
Authors: Richa Saxena; Benjamin F Voight; Valeriya Lyssenko; Noël P Burtt; Paul I W de Bakker; Hong Chen; Jeffrey J Roix; Sekar Kathiresan; Joel N Hirschhorn; Mark J Daly; Thomas E Hughes; Leif Groop; David Altshuler; Peter Almgren; Jose C Florez; Joanne Meyer; Kristin Ardlie; Kristina Bengtsson Boström; Bo Isomaa; Guillaume Lettre; Ulf Lindblad; Helen N Lyon; Olle Melander; Christopher Newton-Cheh; Peter Nilsson; Marju Orho-Melander; Lennart Råstam; Elizabeth K Speliotes; Marja-Riitta Taskinen; Tiinamaija Tuomi; Candace Guiducci; Anna Berglund; Joyce Carlson; Lauren Gianniny; Rachel Hackett; Liselotte Hall; Johan Holmkvist; Esa Laurila; Marketa Sjögren; Maria Sterner; Aarti Surti; Margareta Svensson; Malin Svensson; Ryan Tewhey; Brendan Blumenstiel; Melissa Parkin; Matthew Defelice; Rachel Barry; Wendy Brodeur; Jody Camarata; Nancy Chia; Mary Fava; John Gibbons; Bob Handsaker; Claire Healy; Kieu Nguyen; Casey Gates; Carrie Sougnez; Diane Gage; Marcia Nizzari; Stacey B Gabriel; Gung-Wei Chirn; Qicheng Ma; Hemang Parikh; Delwood Richardson; Darrell Ricke; Shaun Purcell Journal: Science Date: 2007-04-26 Impact factor: 47.728
Authors: Valeriya Lyssenko; Cecilia L F Nagorny; Michael R Erdos; Nils Wierup; Anna Jonsson; Peter Spégel; Marco Bugliani; Richa Saxena; Malin Fex; Nicolo Pulizzi; Bo Isomaa; Tiinamaija Tuomi; Peter Nilsson; Johanna Kuusisto; Jaakko Tuomilehto; Michael Boehnke; David Altshuler; Frank Sundler; Johan G Eriksson; Anne U Jackson; Markku Laakso; Piero Marchetti; Richard M Watanabe; Hindrik Mulder; Leif Groop Journal: Nat Genet Date: 2008-12-07 Impact factor: 38.330
Authors: Eleftheria Zeggini; Michael N Weedon; Cecilia M Lindgren; Timothy M Frayling; Katherine S Elliott; Hana Lango; Nicholas J Timpson; John R B Perry; Nigel W Rayner; Rachel M Freathy; Jeffrey C Barrett; Beverley Shields; Andrew P Morris; Sian Ellard; Christopher J Groves; Lorna W Harries; Jonathan L Marchini; Katharine R Owen; Beatrice Knight; Lon R Cardon; Mark Walker; Graham A Hitman; Andrew D Morris; Alex S F Doney; Mark I McCarthy; Andrew T Hattersley Journal: Science Date: 2007-04-26 Impact factor: 47.728
Authors: Alexandra Winters; Bruno Ramos-Molina; Timothy S Jarvela; Laura Yerges-Armstrong; Toni I Pollin; Iris Lindberg Journal: Diabetes Res Clin Pract Date: 2017-07-03 Impact factor: 5.602
Authors: Rong Yuan; Daniel M Gatti; Rebecca Krier; Ethan Malay; David Schultz; Luanne L Peters; Gary A Churchill; David E Harrison; Beverly Paigen Journal: J Gerontol A Biol Sci Med Sci Date: 2014-07-28 Impact factor: 6.053
Authors: Delf-Magnus Kummerfeld; Boris V Skryabin; Juergen Brosius; Sergey Y Vakhrushev; Timofey S Rozhdestvensky Journal: Int J Mol Sci Date: 2022-08-05 Impact factor: 6.208
Authors: Bianca E Suur; Melody Chemaly; Moritz Lindquist Liljeqvist; Djordje Djordjevic; Markus Stenemo; Otto Bergman; Eva Karlöf; Mariette Lengquist; Jacob Odeberg; Eva Hurt-Camejo; Per Eriksson; Daniel F J Ketelhuth; Joy Roy; Ulf Hedin; Michael Nyberg; Ljubica Matic Journal: Front Pharmacol Date: 2022-09-15 Impact factor: 5.988